Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
Justus G Garweg1,21Swiss Eye Institute, Rotkreuz, and Berner Augenklinik Am Lindenhofspital, Bern, Switzerland; 2Department of Ophthalmology, Inselspital, University of Bern, Bern, SwitzerlandPurpose: To review published evidence for a treatment interval extension to ≥12-weeks in neovascular...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2019-07-01
|
| Series: | Clinical Ophthalmology |
| Subjects: | |
| Online Access: | https://www.dovepress.com/twelve-week-dosing-with-aflibercept-in-the-treatment-of-neovascular-ag-peer-reviewed-article-OPTH |